Beilun Peoples Hospital
Beilun Peoples Hospital
Ying X.,Wenzhou University |
Chen X.,Wenzhou University |
Liu H.,Wenzhou University |
Nie P.,Beilun Peoples Hospital |
And 4 more authors.
European Journal of Pharmacology | Year: 2015
High glucose is one of the possible causes for osteoporosis and fracture in diabetes mellitus. Our previous study showed that silibinin can increase osteogenic effect by stimulating osteogenic genes expression in human bone marrow stem cells (hBMSCs). However, no study has yet investigated the effect of silibinin on osteogenic differentiation of hBMSCs cultured with high glucose. The aim of this study was to evaluate the influence of high glucose on osteogenic differentiation of hBMSCs and to determine if silibinin can alleviate those effects. In this study, the hBMSCs were cultured in an osteogenic medium with physiological (normal glucose, NG, 5.5 mM) or diabetic (high glucose, HG, 30 mM). The effects of silibinin on HG-induced osteogenic differentiation were evaluated by alkaline phosphatas (ALP) activity assay, Von Kossa staining and real time-polymerase chain reaction. HG-induced oxidative damage was also assessed. Western blot were performed to examine the role of PI3K/Akt pathway. We demonstrated that HG suppressed osteogenic differentiation of hBMSCs, manifested by a decrease in expression of osteogenic markers and an increase of oxidative damage markers including reactive oxygen species and lipid peroxide (MDA). Remarkably, all of the observed oxidative damage and osteogenic dysfunction induced by HG were inhibited by silibinin. Furthermore, the PI3K/Akt pathway was activated by silibinin. These results demonstrate that silibinin may attenuate HG-mediated hBMSCs dysfunction through antioxidant effect and modulation of PI3K/Akt pathway, suggesting that silibinin may be a superior drug candidate for the treatment of diabetes related bone diseases. © 2015 Elsevier B.V. All rights reserved.
Wang M.,Beilun Peoples Hospital |
Ma H.,Beilun Peoples Hospital |
Pan Y.,Sun Yat Sen University |
Xiao W.,Beilun Peoples Hospital |
And 3 more authors.
Applied Immunohistochemistry and Molecular Morphology | Year: 2015
Ovarian cancer is the leading cause of cancer-related death in gynecologic malignancies and consists of different histologic types. Histopathologic examination and accurate subtype diagnosis has become increasingly important in guiding patient management and, as such, is the most important currently available ovarian carcinoma "biomarker." In this study, we examined the expression of PAX2 and PAX8 by immunohistochemistry in 58 cases of ovarian serous tumors and 68 cases of ovarian mucinous tumors. The results demonstrated that PAX2 and PAX8 were detected in 100% (30/30) and 77% (23/30) of serous cystadenomas, 100% (16/16) and 94% (15/16) of borderline serous cystadenomas, and 100% (12/12) and 83% (10/12) of serous carcinomas, respectively. However, PAX2 and PAX8 were detected in only 0% (0/29) and 0% (0/29) of mucinous cystadenoma, 4% (1/24) and 4% (1/24) of borderline mucinous cystadenoma, and 0% (0/15) and 7% (1/15) of mucinous carcinoma, respectively. Further, there is a linear correlation between PAX2 and PAX8 (R 2 =0.745; P<0.0001). Overall, our data indicated that PAX2 correlated with PAX8, and these 2 proteins differentially expressed in ovarian serous tumors and ovarian mucinous tumors. Thus, PAX2 and PAX8 are useful biomarker in the differential diagnosis of ovarian serous and mucinous tumors. © 2014 Wolters Kluwer Health, Inc.
Chen J.,Zhejiang University |
Lu X.-Y.,Zhejiang University |
Wang W.-J.,Hangzhou Cancer Hospital |
Shen B.,First Hospital of Jiaxing |
And 4 more authors.
Journal of Pain and Symptom Management | Year: 2014
Context. Cancer treatment capacity in China is severely limited relative to the enormous size of the population; and many aspects of treatment, such as opioid protocols for pain control, are not standardized. To improve the quality of drug treatment, clinical pharmacists are taking a more active role in patient care.Objectives. This study compared the effectiveness of opioid treatment between cancer patients receiving interventions from Clinical Pharmacist-Led Guidance Teams (CPGTs) and a comparable control group.Methods. This was a prospective, multicenter, double-Arm, controlled study conducted in China. Multidisciplinary guidance teams were established and led by clinical pharmacists with expertise in cancer pain therapy. The CPGTs provided pre-Therapy consultation and drug education to physicians, monitored prescriptions during treatment, and conducted patient follow-up. The process and outcome parameters of therapy were collected and analyzed with overall statistics and logistic regression.Results. A total of 542 patients were enrolled, 269 in the CPGT intervention group (CPGT group) and 273 controls. Standardization of opioid administration was improved significantly in the CPGT group, including more frequent pain evaluation (P < 0.001), more standardized dosing titration (P <0.001), and less frequent meperidine prescriptions (P <0.001). The pain scores in the CPGT group were significantly improved compared with the control group (P <0.05). The incidences of gastrointestinal adverse events were significantly lower in the CPGT group (constipation: P = 0.041; nausea: P = 0.028; vomiting: P = 0.035), and overall quality of life was improved (P = 0.032). No opioid addiction was encountered in the CPGT group. Risk analysis revealed that patient follow-up by pharmacists and the controlled dosing of opioids were the major factors in improving treatment efficacy.Conclusion. The CPGTs significantly improved standardization, efficiency, and efficacy of cancer pain therapy in China. In a country where clinical pharmacy is still developing, this is a valuable service model that may enhance cancer treatment capacity and efficacy while promoting recognition of the clinical pharmacy profession. © 2014 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
Du X.,Beilun Peoples Hospital |
Wang J.,Fudan University |
Shao L.,Fudan University |
Hu X.,Fudan University |
And 4 more authors.
Journal of Viral Hepatitis | Year: 2013
The aim of this study was to evaluate the histological outcomes of chronic hepatitis B (CHB) patients with persistently normal alanine aminotransferase (ALT) levels after long-term antiviral therapy. Paired liver biopsies before and after lamivudine (LAM) treatment in CHB patients with normal and elevated ALT levels were compared. Histological response was defined as a 1-point decrease according to the Scheuer scoring system, without worsening of fibrosis between pretreatment and posttreatment biopsies. Among the 48 patients who underwent paired liver biopsies, 17 had persistently normal baseline ALT level and 31 had elevated ALT level. The median age of the patients was 44 years and 72.9% of the patients were male. The median duration of antiviral treatment was 44.5 months (range 14-104). Long-term follow-up of liver biopsies revealed that 82.4% of patients in the normal ALT group and 61.3% in the elevated ALT group had a baseline fibrosis score of 4, which was reduced to 17.6% and 38.7% after long-term therapy, respectively, indicating reversal of cirrhosis in a large proportion of both groups, especially in patients with normal baseline ALT levels. Long-term antiviral treatment could achieve significant histological improvement in CHB patients with fibrosis or cirrhosis, regardless of ALT level. © 2013 Blackwell Publishing Ltd.
Feng Z.-Y.,Zhejiang University |
He Z.-N.,Beilun Peoples Hospital |
Zhang B.,Beilun Peoples Hospital |
Chen Z.,Zhejiang University
Molecular Medicine Reports | Year: 2013
The involvement of osteoprotegerin (OPG) in bone metabolism has previously been established; however, whether OPG regulates chondrocytes directly and exerts precise cellular and molecular effects on chondrocytes remains to be determined. Thus, the present study aimed to investigate the direct effect of OPG on the viability, proliferation and functional consequences of chondrocytes. Primary chondrocytes were isolated from the knee of Sprague-Dawley rats. Passage 1 chondrocytes were identified by toluidine blue staining and used in the experiments. The cell proliferation induced by OPG at various concentrations was measured by a Cell Counting kit-8 (CCK-8) assay. Following pretreatment with mitogen-activated/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126, extracellular signal-regulated kinase (ERK) inhibitor PD098059, and P38 mitogen-activated protein kinase (P38MAPK) inhibitor SB203580 for 30 min, chondrocytes were treated with OPG, and CCK-8 was performed. The cellular signals of MAPKs, including ERK, P38MAPK and c-Jun N-terminal protein kinase (JNK), were investigated by western blot analysis following treatment with OPG. The functional consequences following treatment with soluble OPG were analyzed by qPCR and western blot analysis. OPG increased chondrocyte proliferation with maximal effect at 10 ng/ml, and induced the phosphorylation of MEK and ERK but not P38MAPK or JNK. Suppression of ERK activity via PD098095 inhibited OPG-induced chondrocyte proliferation. Administration of OPG significantly downregulated ADAMTS-5 and upregulated tissue inhibitor of metalloproteinase (TIMP)?4 production, but had no effect on the expression of TIMP-1, -2 and -3, insulin-like growth factor I, transforming growth factor-β, basic fibroblast growth factor, bone morphogenetic protein-2, collagen II, aggrecan and ADAMTS-4. Suppression of ERK activity via PD098095 inhibited the alteration of ADAMTS-5 and TIMP-4 expression induced by OPG. OPG therefore regulated the proliferation of chondrocytes via MEK/ERK signaling, and directly affected chondrocytes by influencing the expression profile of ADAMTS-5 and TIMP-4.
Chen J.,Zhejiang University |
Ye Y.,Beilun Peoples Hospital |
Sun H.,Zhejiang University |
Shi G.,Zhejiang University
Cancer Chemotherapy and Pharmacology | Year: 2013
Purpose: To comparatively evaluate whether metastatic colorectal cancer (mCRC) patients with KRAS codon 13 mutations (codon 13 muts) can benefit from anti-EGFR treatment. Methods: We performed a meta-analysis of relevant studies. Systematic searches of the PubMed, Embase, and Cochrane databases, as well as ASCO conference papers up to July 30, 2012, were retrieved, and the authors of included studies were contacted to obtain more individual data. Fixed effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed. The primary study end points were the overall response rate (ORR). Secondary end points were progress-free survival (PFS) and overall survival (OS). Results: A total of 7 studies were included in the final meta-analysis, consisting of 2,802 mCRC patients, 1,679 of whom were treated with anti-EGFR monoclonal antibodies. The ORR of mCRC patients with codon 13 mutation was 25.2 % (29/115), compared to 17.6 % (98/558) for other KRAS mutations (other mut) and 42.6 % (429/1,006) for KRAS WT patients. The overall pooled RR for ORRs of codon 13 mut versus other mut was 1.52 (95 % CI 1.10-2.09, P = 0.003), whereas the pooled RR for codon 13 mut versus WT was 0.61 (95 % CI 0.45-0.83, P = 0.002). The pooled progression-free survival (PFS) times were 6.4 months for codon 13 mut, 4.1 months for other mut, and 6.6 months for WT, whereas the pooled OS durations were 14.6, 11.8, and 17.3 months, respectively. Subgroup analysis was conducted on the basis of the line of treatment, anti-EGFR drug, study design, and detection method, respectively. The results implicated that KRAS codon 13 mut patients gain more benefit from Cetuximab in further line treatment. Conclusions: Metastatic colorectal cancer patients with KRAS codon 13 mutations demonstrate a greater clinical response to anti-EGFR treatment than patients with other KRAS mutations. © 2012 Springer-Verlag Berlin Heidelberg.
Shen W.,Beilun Peoples Hospital |
Hu J.-A.,Beilun Peoples Hospital |
Zheng J.-S.,Zhejiang University
Journal of International Medical Research | Year: 2014
Objective: To investigate the mechanisms of action of the tumoricidal effects of temozolomide against the human glioma cell line U251 in vitro, and to provide preclinical proof-of-concept studies of the effects of temozolomide-containing regimens. Methods: U251 cells were exposed to 100 μmol/l temozolomide. Morphological alterations were monitored by light microscopy. Cell viability was measured using the 3 -(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell cycle analysis and the rate of apoptosis were determined using flow cytometry and the number of acidic vesicular organelles stained with acridine orange were analysed by fluorescence microscopy. The scratch recovery test was used to measure cell migration. Results: U251 cells that were treated with temozolomide displayed morphological alterations indicative of a rounder shape and impaired cellular adhesion to the cell culture plate compared with control U251 cells. Temozolomide reduced cell viability as measured by the MTT assay, caused cell cycle arrest in the gap 2/mitosis phase, inhibited cell migration and promoted autophagy in U251 cells. Conclusion: Temozolomide induced autophagic, but not apoptotic processes, in U251 cells and thus reduced their viability and migration. © The Author(s) 2013.
Zhao H.,Beilun Peoples Hospital |
Shu G.,Beilun Peoples Hospital |
Wang S.,Beilun Peoples Hospital
International Journal of STD and AIDS | Year: 2015
The role of HIV/AIDS in non-melanoma skin cancer (NMSC) is not well defined. We sought to update the evidence of the association between HIV/AIDS and risk of NMSC by gender and antiretroviral therapy (ART). We searched MEDLINE and EMBASE on 29 February 2014. Standardised incidence ratios with corresponding 95% confidence intervals were extracted and combined using generic inverse variance methods assuming a random effects model. Six studies including 78,794 patients with HIV/AIDS fulfilled the inclusion criteria. Analysis of all studies showed that HIV/AIDS was associated with an increased risk of NMSC (standardised incidence ratio 2.76; 95% confidence interval 2.55–2.98). The standardised incidence ratios of NMSC were 3.63 (1.08–12.22) for men and 2.18 (1.24–3.83) for women with HIV/AIDS, respectively. In analysis stratified by ART, we found that individuals receiving ART had lower risk of developing NMSC than individuals who had not received ART (standardised incidence ratio, 95% confidence interval; 1.95 [1.10–3.47] versus 2.11 [1.44-3.12]). HIV/AIDS is associated with an increased risk of NMSC in both male and female patients. The use of ART appears to be beneficial in protecting against the development of NMSC. © 2015, The Author(s) 2015.
Ma H.,Beilun Peoples Hospital |
Xiao W.,Beilun Peoples Hospital |
Li J.,Beilun Peoples Hospital |
Li Y.,Beilun Peoples Hospital
Surgical Oncology | Year: 2012
Background: Malignant change is a rare complication of alimentary tract duplications. Methods: Articles concerning malignancies arising from alimentary tract duplications published from 1955 to 2012 on PubMed were extensively reviewed. These cases were reclassified and analyzed according to sites of clinical manifestations, diagnostic examinations, methods of management, pathological findings, clinical staging and prognosis. Results: There were 64 citations in the literature that provided adequate descriptions of 67 cases of malignancies arising from alimentary tract duplications near the oesophagus (n = 6), stomach (n = 10), small intestine (n = 19), appendix (n = 1) and large intestine (n = 31). Among the cases described above, 57 underwent surgical treatment. In 43 patients with known prognosis, 7 died of tumour progression. In another 5 cases, the tumours recurred and metastasized recurred and metastasised after surgery at an average of 11.4 months. Conclusions: For relieving symptoms and preventing malignant change, all duplications should be considered for surgery. Unfortunately, prognosis is generally poor once malignancy has occurred in the duplications. © 2012 Elsevier Ltd. All rights reserved.
PubMed | Beilun Peoples Hospital
Type: Journal Article | Journal: International journal of STD & AIDS | Year: 2016
The role of HIV/AIDS in non-melanoma skin cancer (NMSC) is not well defined. We sought to update the evidence of the association between HIV/AIDS and risk of NMSC by gender and antiretroviral therapy (ART). We searched MEDLINE and EMBASE on 29 February 2014. Standardised incidence ratios with corresponding 95% confidence intervals were extracted and combined using generic inverse variance methods assuming a random effects model. Six studies including 78,794 patients with HIV/AIDS fulfilled the inclusion criteria. Analysis of all studies showed that HIV/AIDS was associated with an increased risk of NMSC (standardised incidence ratio 2.76; 95% confidence interval 2.55-2.98). The standardised incidence ratios of NMSC were 3.63 (1.08-12.22) for men and 2.18 (1.24-3.83) for women with HIV/AIDS, respectively. In analysis stratified by ART, we found that individuals receiving ART had lower risk of developing NMSC than individuals who had not received ART (standardised incidence ratio, 95% confidence interval; 1.95 [1.10-3.47] versus 2.11 [1.44-3.12]). HIV/AIDS is associated with an increased risk of NMSC in both male and female patients. The use of ART appears to be beneficial in protecting against the development of NMSC.